Idorsia announced results from the phase 3 MODIFY trial which evaluated lucerastat as monotherapy for the treatment of adult patients with Fabry disease. The trial…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.